

Docket No. 258087US0X PCT

10/506334 #3
DY09 PCT/PTO 02 SEP 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Boris LINARD, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/FR03/00698

GAU:

FILED: Herewith

EXAMINER:

FOR: PEPTIDES FOR USE IN ANTITUMOR IMMUNOTHERAPY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. In accordance with discussions on August 4, 2004 with Mr. Nicholas P. Godici, Commissioner for Patents, it is no longer required to submit copies of cited pending applications. A modification of the Rules will be published soon in the Official Gazette. Cited issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

DT09 REC'D STARTED 02 SEP 2004

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 258087US0X PCT	SERIAL NO. New U.S. PCT Application Based on PCT/FR03/00698			
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Francine JOTEREAU, et al.				
		FILING DATE Herewith				
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						
AM						
AN						
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
AO	01/90197	11/29/01	WO			NO
AP	01/16320	03/08/01	WO			NO
AQ	00/21551	04/20/00	WO			NO
AR	01/53833	07/26/01	WO			NO
AS						
AT						
AU						
AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)						
AW	ROMERO, P. et al. "Therapeutic cancer vaccines based on molecularly defined human tumor antigens", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB. vol.20, pages A2-A7, XP004397465, ISSN: 0264-410X 12/19/2002					
AX	MENDEZ, R et al. "Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy." TISSUE ANTIGENS. DENMARK, vol.57, no.6, pages 508-519, XP002265728 ISSN: 0001-2815 06/2001					
AY	VALMORI, D. et al. "Diversity of the Fine Specificity Displayed by HLA-A*0201-Restricted CTL Specific for the Immunodominant Melan-A/MART-1 Antigenic Peptide," Journal of Immunology, The Williams and Wilkins Co. Baltimore, US, vol.161, no.12, pages 6956-6962 XP00086281, ISSN: 0022-1767 1998					
AZ	BENLALAM, H. et al. "Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy." European Journal of Immunology. Germany, vol. 31, no. 7, pages 2007-2015, XP002265727, ISSN: 0014-2980 07-2001				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner						
Date Considered						
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						